• Chairman Chung attends 2026 World Economic Forum Annual Meeting for fourth consecutive year
• Discusses AI-driven transformation and innovation in energy transition at key sessions
• Met with Palantir co-founder and CEO Alex Karp to discuss expansion of strategic partnership

SEOUL, South Korea, Jan. 21, 2026 /PRNewswire/ — HD Hyundai Chairman Chung Kisun attended the 2026 World Economic Forum (WEF) Annual Meeting, also known as the Davos Forum, in Davos, Switzerland, where he discussed the future of artificial intelligence (AI) and the energy industry.

The Davos Forum brings together leaders from government, business and academia from around the world to address global challenges and explore its solutions. This year’s meeting runs from January 19 to 23 under the theme “A Spirit of Dialogue.” Chairman Chung first attended the forum in 2023 and is participating for the fourth consecutive year.

At this year’s forum, Chairman Chung attended key official sessions and held wide-ranging discussions with global leaders on industry transformation driven by AI; the growing importance of accessibility, resilience and AI as core pillars of the energy transition; and the risk of a slowdown in global growth amid geopolitical shifts, along with strategies to address those challenges.

Chairman Chung is also scheduled to attend the Oil & Gas Governors meeting, following his participation last year, to exchange views on changes in the global energy market, the energy transition, energy security and technological innovation.

On the second day of the forum, January 20, local time, he met with Alex Karp, co-founder and CEO of Palantir Technologies, and agreed to expand the strategic partnership between HD Hyundai and the global enterprise AI company.

With the expanded partnership, HD Hyundai plans to further its existing collaboration with Palantir and broaden cooperation across the group, including key affiliates such as HD Hyundai Electric, HD Hyundai Robotics and HD Hyundai Marine Solution, as it accelerates its digital transformation. Since 2021, beginning with HD Hyundai Oilbank, the group has deployed Palantir’s big data solutions and Artificial Intelligence Platform (AIP) across its core businesses, including shipbuilding and offshore operations, energy and construction equipment, establishing a data-driven decision-making framework.

“This expanded strategic partnership marks an important turning point in connecting data and workflows across HD Hyundai into a single, cohesive system—enabling faster and more sophisticated decision-making” said Chung Kisun, Chairman of HD Hyundai. He added, “Palantir is a partner with globally proven capabilities in data integration, operational optimization, and AI-driven analytics, and will add strength in executing HD Hyundai’s digital transformation.”

“HD Hyundai is a pioneering force in global industry, and the significant expansion of our partnership marks an exciting new chapter,” said Dr. Alex Karp, co-founder and CEO of Palantir Technologies. “We are committed to advancing our strategic collaboration and driving the group’s competitiveness, and we look forward to continue building together.”

Looking ahead, HD Hyundai plans to jointly establish a Center of Excellence with Palantir to systematically embed advanced data analytics and artificial intelligence capabilities across the organization, while securing sustainable growth engines to support AI-driven innovation.

TULSA, Okla., Jan. 21, 2026 /PRNewswire/ — T.D. Williamson (TDW), a global leader in pipeline solutions, announced the launch of TDW SHiiELD™, a next-generation pipeline isolation tool creating a new standard of double independent isolation and bleed (DiiB).

Industry-first pipeline isolation solution

SHiiELD technology delivers leak-proof performance, uncompromising safety, and four times the throughput area of traditional double block-and-bleed solutions while protecting the environment from fugitive emissions and reducing operational downtime.

Engineered with two independently anchored modules and energized seals, SHiiELD provides a redundant isolation system that exceeds evolving safety and environmental standards. By achieving a certified, leak-proof seal and enabling remote activation and monitoring, SHiiELD minimizes operational risk, enhances pipeline efficiency, and ensures zero-emission isolation projects.

Watch the SHiiELD™ video at tdw.red/SHiiELD to get up to speed on what the system delivers.

Driving efficiency, safety, and environmental responsibility

“SHiiELD is changing the game of how operators isolate pipelines while meeting their emissions and safety goals,” said TDW Chief Executive Officer Bob McGrew. “By combining true redundancy with best-in-class throughput and remote activation, SHiiELD ensures the safest possible isolation for personnel and the environment. This innovative technology underscores TDW’s commitment to advancing pipeline safety and operational efficiency.”

With SHiiELD, TDW continues to drive the pipeline industry forward with advanced technologies that meet the market’s demand for higher safety, reliability, environmental responsibility, and throughput. Read our blog to learn how DiiB technology works.

Shiield is a trademark of T.D. Williamson, Inc. For more information about the TDW SHiiELD System, visit us online.

About T.D. Williamson

T.D. Williamson (TDW) delivers advanced pipeline integrity, intervention, pigging and repair technologies that keep critical energy systems operating safely and efficiently. For more than a century, TDW has led innovation in pigging and isolation solutions that reduce emissions, extend asset life, and support a more sustainable energy future.

Today, TDW supports the energy industry’s drive toward lower-carbon operations and a sustainable pipeline future. With headquarters in Tulsa, Oklahoma, TDW operates in more than 35 locations across the globe, with channel partners across Europe, Asia, and the Middle East.

BEIJING, Jan. 21, 2026 /PRNewswire/ — For 20 years, Beijing InfoComm China has served as the most professional and influential platform for promoting and expanding China’s global Professional Audio-Visual (Pro-AV) industry. Through decades of bringing together manufacturers, solution providers, IT system integrators, and end users of Pro-AV, Beijing InfoComm China has become Asia’s premier Hub for Pro-AV excellence. Taking place from 15-17 April 2026, at the China National Convention Center (CNCC), the show marks the beginning of a landmark era: the 20^th year of the InfoComm China brand, followed by the 20^th edition of the tradeshow in 2027. From an exhibition floor hosting over 400 companies and welcoming over 26,000 professional visitors, to a world-class conference lineup of Pro-AV industry movers & shakers, to delighting audiences with innovative and immersive themed zones.

To commemorate this milestone era, InfoComm China will host a series of events and initiatives throughout the two years honoring the companies, ideas, and people who have help to shape the Pro-AV industry. Leading up to the 2026 event, members of the InfoComm China community can expect even more innovations, interactive programs, and surprises which spotlights the history of Pro-AV, modern-day successes, and future forward showcases launching us into the 2^nd half of the 21^st century.

A US $98 Billion Market Opportunity
With the APAC Pro-AV market valued at US $123.7 billion and China accounting for nearly 80% of the pie (US $98.4 billion and 4.2% CAGR), InfoComm China provides a critical gateway for global trade and technological exchange.

New International Visitor Initiatives
Making a strategic shift toward global integration, InfoComm China for the first time has launched a suite of international visitor initiatives including tools and resources for overseas visiting professionals to navigate their way to China, through the fair, and efficiently network and conduct business deals. Initiatives include the launch of invited guest program with travel hosting privileges, onsite assistance with dedicated lounges and translation services, and a curated selection of “ready-to-export” companies specifically prepared to meet with overseas guests at the show.

For more information on InfoComm China, the international visitor program benefits, and to pre-register your pass to the future visit infocomm-china.com.

For more information, visit:
infocomm-asia.com | infocomm-china.com | infocomm-india.com 

Global Media Enquiries:
Angie Eng
Director, Marketing, InfoCommAsia Pte Ltd
T: +65 8163 2109
E: media@infocommasia.com; angieeng@infocommasia.com

SINGAPORE, Jan. 21, 2026 /PRNewswire/ — The partnership between NLCS (Singapore) and the Wheelchair Rugby Association Singapore began through the initiative of an NLCS (Singapore) student who, after becoming involved with the association, learned that WRAS was at risk of losing access to its long-standing training venue. Recognising the significance of the programme and the impact it has on its athletes, the student brought a detailed proposal to senior staff, advocating for meaningful, long-term support.

That proposal led to a formal partnership in which NLCS (Singapore) committed both sustained sponsorship and access to its sporting facilities, enabling WRAS athletes to practise, and host matches in a stable and supportive environment. The partnership reflects the school’s belief in student leadership and in education that extends beyond the classroom.

WRAS has since continued to grow as a competitive and inclusive sporting community, providing athletes with opportunities to train at a high level while fostering resilience, teamwork, and a strong sense of belonging.

“Wheelchair rugby fosters community inclusion and belonging by providing a structured, supportive environment where individuals with disabilities can participate in a demanding team sport,” said Clare, Secretary and Volunteer at the Wheelchair Rugby Association Singapore.

The strength of this partnership was evident at a recent ceremony, where WRAS athletes were presented with their national jerseys ahead of their participation in the ASEAN Para Games. The event was a moving occasion, celebrating not only sporting excellence but also the collective effort behind the athletes’ journey.

Paul Friend, Director of NLCS (Singapore), attended the ceremony and reflected on the relationship between the school and WRAS:

“This partnership began because one of our students saw something important at risk and was determined to act. What followed was a thoughtful, well-argued case for how we could help in a way that really mattered. Supporting WRAS has been immensely rewarding, not just because of what it enables for the athletes, but because of what our own students learn through being connected with such inspiring people. It is a relationship from which we have all benefited.”

NLCS (Singapore) looks forward to continuing its partnership with WRAS and to supporting the athletes as they compete on the regional stage, while remaining committed to student-led initiatives that create meaningful impact beyond the school community.

About North London Collegiate School (Singapore)  

Founded in August 2020, North London Collegiate School (Singapore) is a British International School offering the academically ambitious NLCS curriculum, followed by the International Baccalaureate (IB) Middle Years Programme and culminating in the IB Diploma Programme. 

Drawing on 175 years of educational heritage from its founding school in the UK, NLCS (Singapore) nurtures individuals to be intellectually curious, socially confident, and grounded in compassion through a rigorous academic framework, rich co-curricular opportunities, and exceptional pastoral care.

Situated on Depot Road, the School is part of a global family of schools committed to educational excellence and developing global citizens.

To learn more about NLCS (Singapore), please visit our website (https://nlcssingapore.sg/) and follow us on Instagram, Facebook, YouTube, and LinkedIn.

For media enquiries, please contact the NLCS (Singapore) Marketing Team
Email: marketing@nlcssingapore.sg

• Japan’s Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases
• Enhances strong global regulatory momentum, including multiple FDA expedited programs and five EMA Orphan designations
• FDA, EMA and PMDA conditionally approve the MOGENRY™ brand name
• Strengthens global pre-commercialization readiness and reinforces leadership in optogenetic therapy

DALLAS, Jan. 21, 2026 /PRNewswire/ — Nanoscope Therapeutics, Inc., a biotechnology company developing disease-agnostic therapies for vision loss caused by retinal degeneration, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted both Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations to MCO-010, its lead optogenetic therapy for patients with severe vision loss from inherited retinal dystrophies (IRDs). Approximately 50,000 patients in Japan are affected by IRDs.

Sakigake is Japan’s premier fast-track regulatory program for innovative therapies addressing serious unmet medical needs. The designation enables prioritized regulatory consultation and review—often targeting a six-month review timeline—through collaboration with the Pharmaceuticals and Medical Devices Agency (PMDA) and may support premium pricing following approval. Combined with Orphan Drug designation for rare, high-need conditions, the decision establishes a clear regulatory pathway for MCO-010 in Japan and marks the first Sakigake designation granted to a retinal gene therapy.

“These designations represent an important milestone for Nanoscope and for patients living with inherited retinal diseases,” said Samarendra Mohanty, PhD, President and Chief Scientific Officer of Nanoscope Therapeutics. “Sakigake recognition underscores the novelty of MCO-010 and its potential to address profound vision loss where no approved treatments exist. Together with our progress in the U.S. and Europe, we are advancing one of the most comprehensive global regulatory strategies in optogenetic retinal gene therapy.”

The MHLW decision builds on strong regulatory momentum across major markets, including five Orphan designations from the European Medicines Agency (EMA) and multiple expedited programs from the U.S. Food and Drug Administration (FDA) across retinal indications. In addition, the FDA, EMA and PMDA have conditionally approved the MOGENRY™ brand name, as Nanoscope continues to advance its rolling Biologics License Application (BLA) for retinitis pigmentosa in the United States.

With regulatory pathways now established in Japan, the United States, and Europe, MCO-010 is positioned as the most advanced optogenetic platform therapy in development worldwide.

Contact:
Nanoscope Therapeutics, Inc
(817) 857-1186
PR@nanostherapeutics.com

Logo – https://laotiantimes.com/wp-content/uploads/2026/01/nscope_nu_horizontal_2color_1200px_logo.jpg

Momentum builds behind AI partnership following last year’s announcement of a 5GW UAE–US AI Campus and chip approvals as leaders meet in Davos

DAVOS, Switzerland, Jan. 21, 2026 /PRNewswire/ — Today, on the sidelines of the World Economic Forum Annual Meeting in Davos, G42 Group CEO Peng Xiao joined David Sacks, White House Advisor on Artificial Intelligence and Cryptocurrency, for a timely discussion on the future of U.S.–UAE AI cooperation and what it will take to compete at scale in the global AI race.

G42

As AI rapidly moves from experimentation to mass adoption, the panel underscored a central reality that AI leadership will be defined by ecosystem partnerships, infrastructure readiness, and access to energy and compute at unprecedented scale. Speaking at the UAE Pavilion, Sacks highlighted the UAE, and G42, as a critical partner in enabling this next phase of AI growth, emphasizing the importance of trusted partners that can deliver gigawatt-scale power and deploy AI on U.S. technology stacks.

From G42’s perspective, Xiao shared insights from building and operating AI infrastructure at scale, stressing that trust, execution, and long-term investment are foundational to success. He highlighted the UAE’s unique ability to support global AI workloads efficiently from Abu Dhabi, reaching billions of users worldwide with ultra-low latency, and reinforced the role of AI diffusion in sustaining U.S. leadership.

The conversation follows major milestones in U.S.–UAE AI collaboration, including the announcement of a planned 5GW UAE–U.S. AI Campus, the largest outside the United States, and recent U.S. approvals supporting advanced AI compute for G42.

Watch the full conversation to hear how U.S.–UAE AI cooperation is shaping the future of global AI leadership here: https://youtu.be/dF2SollBR_k

About G42
G42 is a technology holding group and a global leader in artificial intelligence, delivering impactful solutions across sectors including government, healthcare, energy, finance, and space. Headquartered in Abu Dhabi and operating worldwide, G42 is building the Intelligence Grid to deliver intelligence on demand, securely and at scale.
For more information, visit www.g42.ai

Media Contact
For more information, please contact: G42@trailrunnerint.com 

DEERFIELD, Ill., Jan. 21, 2026 /PRNewswire/ — Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met with enthusiastic adoption by surgical teams who value convenience, versatility, and clinical performance.

Hemopatch in the OR

Hemopatch Sealing Hemostat is a ready-to-use, absorbable collagen pad designed for tissue sealing and hemostasis.¹ The new room temperature format eliminates the need for refrigeration, streamlining preparation and storage in operating rooms.¹ Surgeons across the region are finding significant value in the product’s ability to manage mild to moderate bleeding scenarios with confidence.

“Hemopatch Sealing Hemostat is an excellent product that is quite versatile across many urological operations. The ability to handle venous bleeding across wide surfaces is great for patients and has allowed me to confidently use Hemopatch Sealing Hemostat,” said Urological Surgeon, A/Prof Matthew Roberts from Queensland, Australia.

Baxter is proud to deliver meaningful value to clinicians through innovations like Hemopatch Sealing Hemostat, and empowering surgical teams in achieving their desired patient outcomes. The product’s strong reception underscores our commitment to providing solutions that help save and sustain lives.

With a shelf life of up to 36 months and compatibility with both open and minimally invasive procedures, Hemopatch Sealing Hemostat continues to be a trusted tool in operating rooms across Australia and New Zealand.¹

For more information on Hemopatch Sealing Hemostat,  
Visit: https://advancedsurgery.baxter.eu/hemopatch 

Reference:

1. Hemopatch sealing hemostat Instructions for Use.

Manufacturer:

Baxter Healthcare SA
Thurgauerstrasse 130 Glattbrugg,
ZÜRICH, 8152 Switzerland

Class of Device: III
CE0123

This content is intended solely for healthcare professionals and should not be interpreted as medical advice. Please consult with a qualified healthcare provider for any health concerns.

Hemopatch sealing hemostat is approved for use only in selected countries. For specific information on the availability and regulatory status of Hemopatch sealing hemostat room temperature in your country, we recommend contacting your local Baxter Healthcare sales representative.

Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries.

GBU-AS21-250032 (v1.0) 01/2026

Hemopatch Australia IRI

Photo – https://laotiantimes.com/wp-content/uploads/2026/01/hemopatch_or.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2026/01/hemopatchiri_au.jpg